AON-D21

DRUG3 trials

Sponsors

Aptarion Biotech AG

Conditions

Community-acquired PneumoniaHealthySevere Community-Acquired Pneumonia

Phase 1

Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects.

CompletedNCT05343819

Aptarion Biotech AGHealthy

Start: 2022-04-12End: 2022-11-29Updated: 2022-12-19

Phase 2

Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.

CompletedNCT05962606

Aptarion Biotech AGCommunity-acquired Pneumonia

Start: 2024-02-02End: 2026-03-16Updated: 2026-03-18

An Exploratory, Multi-Centre, Interventional, Prospective, Randomised, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of AON-D21 in Patients with Severe Community-Acquired Pneumonia.

Active, not recruitingCTIS2023-505985-28-01

Aptarion Biotech AGSevere Community-Acquired Pneumonia

Start: 2024-03-04Target: 130Updated: 2025-02-19